Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01181882 · ClinicalTrials.gov registry record · Phase 2

Fish Oil and Aspirin With Type 2 Diabetes

A Phase 2 study, sponsored by University of Rochester.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT01181882: Completed Phase 2 study, sponsored by University of Rochester.

NCT01181882 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01181882, a Phase 2 study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this study is to understand if omega-3 fatty acids in fish oil enhance the ability of aspirin to reduce the risk of cardiovascular diseases such as heart attack and stroke in those who have diabetes mellitus.

Primary Outcome

Platelet function effect will be measured with aspirin alone and 4 hours later, after fish oil ingestion.

Interventions

  • DIETARY_SUPPLEMENT Fish Oil and Aspirin

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-08
Est. Completion 2012-11
Phase Phase 2
University of Rochester

636 total trials

What the finished NCT01181882 record still lists

NCT01181882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 1 intervention - of which Fish Oil and Aspirin is the first listed.

NCT01181882 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01181882 about?

NCT01181882 is a clinical study titled "Fish Oil and Aspirin With Type 2 Diabetes". The purpose of this study is to understand if omega-3 fatty acids in fish oil enhance the ability of aspirin to reduce the risk of cardiovascular diseases such as heart attack and stroke in those who have diabetes mellitus.

What is the current status of trial NCT01181882?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-08. Estimated completion is 2012-11.

What interventions are being tested in trial NCT01181882?

The interventions under investigation include: Fish Oil and Aspirin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01181882?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01181882's enrollment target sits among peer trials

30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01181882, the US trial registry maintained by the National Library of Medicine. NCT01181882 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.